These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 1681816

  • 21. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
    Douglas AM, Atchison BA, Somogyi AA, Drummer OH.
    Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
    [No Abstract] [Full Text] [Related]

  • 22. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L, Meese CO, Yue QY, Dahl ML, Ingelman-Sundberg M, Johansson I, Säwe J, Eichelbaum M.
    Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
    [Abstract] [Full Text] [Related]

  • 23. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population.
    Kondo I, Yonaha M, Okano K, Gonzalez FJ, Kanazawa I.
    Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247
    [Abstract] [Full Text] [Related]

  • 24. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
    Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M.
    Proc Natl Acad Sci U S A; 1993 Dec 15; 90(24):11825-9. PubMed ID: 7903454
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
    Sachse C, Brockmöller J, Bauer S, Roots I.
    Am J Hum Genet; 1997 Feb 15; 60(2):284-95. PubMed ID: 9012401
    [Abstract] [Full Text] [Related]

  • 27. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H, Caporaso NE, Shaw GL, Modali RV, Gonzalez FJ, Hoover RN, Resau JH, Trump BF, Weston A, Harris CC.
    Carcinogenesis; 1990 Sep 15; 11(9):1527-30. PubMed ID: 1976046
    [Abstract] [Full Text] [Related]

  • 28. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype.
    Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T, Kinoshita M, Sato K, Gonzalez FJ, Kamataki T.
    Pharmacogenetics; 1996 Oct 15; 6(5):395-401. PubMed ID: 8946471
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
    Bathum L, Johansson I, Ingelman-Sundberg M, Hørder M, Brøsen K.
    Pharmacogenetics; 1998 Apr 15; 8(2):119-23. PubMed ID: 10022749
    [Abstract] [Full Text] [Related]

  • 32. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.
    Turgeon J, Evans WE, Relling MV, Wilkinson GR, Roden DM.
    Br J Clin Pharmacol; 1991 Sep 15; 32(3):283-8. PubMed ID: 1685663
    [Abstract] [Full Text] [Related]

  • 33. Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.
    Evans WE, Relling MV.
    Mol Pharmacol; 1990 May 15; 37(5):639-42. PubMed ID: 1971090
    [Abstract] [Full Text] [Related]

  • 34. Molecular mechanisms of genetic polymorphisms of drug metabolism.
    Meyer UA, Zanger UM.
    Annu Rev Pharmacol Toxicol; 1997 May 15; 37():269-96. PubMed ID: 9131254
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.
    Roots I, Brockmöller J, Drakoulis N, Loddenkemper R.
    Clin Investig; 1992 May 15; 70(3-4):307-19. PubMed ID: 1355678
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.
    Caporaso NE, Shields PG, Landi MT, Shaw GL, Tucker MA, Hoover R, Sugimura H, Weston A, Harris CC.
    Environ Health Perspect; 1992 Nov 15; 98():101-5. PubMed ID: 1362537
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.